Anaes Vivas · Applied cardiovascular & respiratory physiology
Data viva — pharmacogenetic polymorphisms
A Primary data viva — read a table of classic pharmacogenetic polymorphisms; explain the CYP450 poor/intermediate/extensive/ultra-rapid phenotypes and the prodrug-versus-inactivated-drug distinction; give the clinical implication of CYP2D6/codeine, butyrylcholinesterase/suxamethonium, TPMT/azathioprine and G6PD/oxidant drugs.
On this page
Study tools
Target exams
Stimulus
A table lists four pharmacogenetic polymorphisms — CYP2D6 (drug codeine; consequence poor metaboliser no analgesia, ultra-rapid overdose), butyrylcholinesterase (drug suxamethonium; consequence prolonged paralysis), TPMT (drug azathioprine; consequence myelosuppression), and G6PD (drug primaquine; consequence haemolysis). Interpret the table, explain the metaboliser-phenotype concept, and give the anaesthetic implications of each row.
References3ShowHide
- [1]Thamilselvan M, et al. Distribution of Cytochrome P450 Metabolizer Status and Allelic Variants in Individuals with Mental Health Disorders in Ontario, Canada: Répartition du statut métabolique du cytochrome P450 et des variantes alléliques chez les personnes atteintes de problèmes de santé mentale en Ontario, au Canada. Can J Psychiatry, 2026.PMID 42240275
- [3]Kempff-Andersen S, et al. Butyrylcholinesterase activity and prolonged mivacurium. Eur J Anaesthesiol, 2026.PMID 42298973
- [6]Khaliq A, et al. Anesthetic Management of a Pediatric Patient With Glucose-6-Phosphate Dehydrogenase Deficiency Undergoing Emergency Rigid Esophagoscopy: A Case Report. Cureus, 2026.PMID 42281694